Patients with pathogenic variants in the Capn3, Dysf, Fkrp, and the sarcoglycan genes demonstrated a decline in FVC over time, with the FVCpp declining faster for Fkrp and LGMD-SCG patients and slower for Capn3 and Dysf patients. This evidence concerns the gene CAPN3 and limb-girdle muscular dystrophy.